



“Building a Translational Toolbox: Molecular Imaging in Neurodegenerative Disorders”

Kenneth Marek, M.D.
President, Co-Founder, Senior Scientist
Institute for Neurodegenerative Disorders, New Haven, CT

Wednesday, November 5th, 2014, 8:00 am, Brady Auditorium, Room B131

*This course will fulfill the licensure requirement set forth by the State of Connecticut
This Grand Rounds Activity is not supported by any Educational Grant*

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Yale School of Medicine designates this educational activity for 1 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

NEEDS ASSESSMENT

This talk will provide a description of PET & SPECT radioligand development & application for both understanding pathobiology & developing therapeutics for neurodegenerative disorders. Specific examples of the utility of radiotracers for diagnosis & disease monitoring will be discussed. The role of radiotracers to identify at risk subjects during the prodromal stage of disease.

FACULTY DISCLOSURES

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will understand:

The role of imaging biomarkers in neurodegenerative disorders

The need for early and accurate identification of at risk subjects with neurologic disease

To describe the steps and pitfalls in development of radiotracer for neurologic disease